TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03418220

Intervention type: OTHER
Group type: OTHER
Intervention: blood and aqueous humor sampling
Description: The blood sample will be centrifuged. The plasma will be recovered. Plasma and aqueous humor will be frozen and stored at -80° Celsius. The search of 27 markers of inflammation will be performed by the kit LUMINEX Bio-rad (Bio-Rad, M500KCAF0Y).

Intervention type: OTHER
Group type: OTHER
Intervention: blood and aqueous humor sampling
Description: The blood sample will be centrifuged. The plasma will be recovered. Plasma and aqueous humor will be frozen and stored at -80° Celsius. The search of 27 markers of inflammation will be performed by the kit LUMINEX Bio-rad (Bio-Rad, M500KCAF0Y).

Intervention type: OTHER
Group type: OTHER
Intervention: blood and aqueous humor sampling
Description: The blood sample will be centrifuged. The plasma will be recovered. Plasma and aqueous humor will be frozen and stored at -80° Celsius. The search of 27 markers of inflammation will be performed by the kit LUMINEX Bio-rad (Bio-Rad, M500KCAF0Y).

Intervention type: OTHER
Group type: OTHER
Intervention: blood and aqueous humor sampling
Description: The blood sample will be centrifuged. The plasma will be recovered. Plasma and aqueous humor will be frozen and stored at -80° Celsius. The search of 27 markers of inflammation will be performed by the kit LUMINEX Bio-rad (Bio-Rad, M500KCAF0Y).
Study: NCT04139434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP-108
Description: For the dose escalation phase, LP-108 will be given once daily at the following dose levels: 100 mg QD, 200 mg QD, 400 mg QD, 600 mg QD, 800 mg QD, 1000 mg QD.
Study: NCT02482792

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Norwegian Psychomotor Physiotherapy
Description: The recruited patients will after randomization receive either Norwegian Psychomotor Physiotherapy (NPMP) or COPE combined with active individual physiotherapy. In NPMP the treatment is individualized, targeting body-mind awareness through exercise, massage and therapeutic conversation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Patient Education and PT
Description: The comparison group will receive a combination of education about how to manage pain (COPE) followed by active individual physiotherapy.
Study: NCT04369872

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microwave ablation
Description: Microwave ablation of lung lesion using Solero Microwave Tissue Ablation system.
Study: NCT02019004

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Onabotulinum Toxin A

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Incobotulinum Toxin A
Study: NCT02797769

Intervention type: DRUG
Intervention: Other Biologics
Description: Exposure data will be gathered from claims databases, and no medicine will be administered in this non-interventional study. There are no protocol-specified biologic agents, although the analyses will be stratified by TNFi and non-TNFi targeted therapies. The drug selection and regimen are at the discretion of the prescribing physician.

Intervention type: DRUG
Intervention: Other Biologics
Description: Exposure data will be gathered from claims databases, and no medicine will be administered in this non-interventional study. There are no protocol-specified biologic agents, although the analyses will be stratified by TNFi and non-TNFi targeted therapies. The drug selection and regimen are at the discretion of the prescribing physician.

Intervention type: DRUG
Intervention: Tocilizumab
Description: Tocilizumab exposure data will be gathered from claims databases, and no medicine will be administered in this non-interventional study. The regimen is at the discretion of the prescribing physician.
Study: NCT04819867

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propolis
Description: propolis is an extract derived from bee hives

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gluma Desensitizer
Description: Gluma is a desensitizer agent
Study: NCT02812108

Intervention type: DEVICE
Intervention: intracranial stent, flow diverter and coils
Study: NCT03547349

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Digital Incentive Spirometer
Description: This device is an incentive spirometer connected to a tablet interface. This tablet device uses a digital interface to mimic the look and function of the standard issue incentive spirometer

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Digital Incentive Spirometer
Description: This device is an incentive spirometer connected to a tablet interface. This tablet device uses a digital interface to mimic the look and function of the standard issue incentive spirometer

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Digital Incentive Spirometer
Description: This device is an incentive spirometer connected to a tablet interface. This tablet device uses a digital interface to mimic the look and function of the standard issue incentive spirometer

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Jamboxx Respiratory Therapy Device
Description: THe Jamboxx Respiratory Therapy Device is a novel device that uses interactive gaming to encourage patient compliance with their prescribed respiratory therapy routines. The device consists of a computer game controller with mouthpiece, and breath flow sensor that connects to a tablet. With the Jamboxx Respiratory Therapy Device, users can choose from a suite of breath controlled respiratory therapy games to guide them through their routines while receiving real-time feedback, and long-term progress tracking.
Study: NCT02030093

Intervention type: BEHAVIORAL
Intervention: Telephone-based counseling
Description: Telephone-based continuing care wil be provided to patients in different frequency

Intervention type: BEHAVIORAL
Intervention: Telephone-based counseling
Description: Telephone-based continuing care wil be provided to patients in different frequency

Intervention type: BEHAVIORAL
Intervention: Telephone-based counseling
Description: Telephone-based continuing care wil be provided to patients in different frequency

Intervention type: BEHAVIORAL
Intervention: Telephone-based counseling
Description: Telephone-based continuing care wil be provided to patients in different frequency
Study: NCT04587895

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VITAAL Exergame
Description: 12 weeks training with the VITAAL Exergame. The VITAAL exergame is an individualized multicomponent exergame training based mostly on the prevention and slowing of physical and cognitive decline and its consequences. It mainly consists of three (four with UI) components; strength training, balance training, cognitive training and pelvic floor muscle training (PFMT) when suffering from UI.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VITAAL Exergame
Description: 12 weeks training with the VITAAL Exergame. The VITAAL exergame is an individualized multicomponent exergame training based mostly on the prevention and slowing of physical and cognitive decline and its consequences. It mainly consists of three (four with UI) components; strength training, balance training, cognitive training and pelvic floor muscle training (PFMT) when suffering from UI.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Training UI
Description: 12 weeks non-individualized conventional training with a training booklet and additional walking exercise. The PFM training booklet is based on exercises that showed a reduction of incontinence in older adults while performing group pelvic floor muscle training (PFMT) and mobility exercises.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Training MI
Description: 12 weeks non-individualized conventional training with a training booklet and additional walking exercise. The exercises are based on recommendations from the Beratungsstelle für Unfallverhütung (bfu).
Study: NCT00044694

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 0.01 mL
Description: 2-week placebo lead-in period (0.01 mL) followed by 4 weeks of Placebo 0.01 mL subcutaneously injected twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 0.02 mL
Description: 2-week placebo lead-in period (0.01 mL) followed by 4 weeks of Placebo 0.02 mL subcutaneously injected twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 0.03 mL
Description: 2-week placebo lead-in period (0.01 mL) followed by 4 weeks of Placebo 0.03 mL subcutaneously injected twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 0.04 mL
Description: 2-week placebo lead-in period (0.01 mL) followed by 4 weeks of Placebo 0.04 mL subcutaneously injected twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC2993 2.5 mcg
Description: 2-week placebo lead-in period (0.01 mL) followed by 4 weeks of AC2993 2.5 mcg (0.01 mL) subcutaneously injected twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC2993 5.0 mcg
Description: 2-week placebo lead-in period (0.01 mL) followed by 4 weeks of AC2993 5.0 mcg (0.02 mL) subcutaneously injected twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC2993 7.5 mcg
Description: 2-week placebo lead-in period (0.01 mL) followed by 4 weeks of AC2993 7.5 mcg (0.03 mL) subcutaneously injected twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AC2993 10.0 mcg
Description: 2-week placebo lead-in period (0.01 mL) followed by 4 weeks of AC2993 10.0 mcg (0.04 mL) subcutaneously injected twice daily
Study: NCT02210455

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strongest Families FASD intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Psychoeducation

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Psychoeducation
Study: NCT04139434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LP-108 and azacitidine
Description: For the dose escalation phase, LP-108 will be given once daily at the following dose levels: 100 mg QD, 200 mg QD, 400 mg QD, 600 mg QD, 800 mg QD, 1000 mg QD, with azacitidine at the standard dose of 75 mg/m2 on Day 1 - Day 7 of each 28-day cycle (weekly schedule) or on Days 1-5, 8, 9 of each 28-day cycle (5-2-2 schedule), according to institutional guidelines.
Study: NCT01070706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel,Gemcitabine,Sunitinib
Description: To determine the MTD, only DLT occurring during the first cycle of treatment will be considered. And MTD is defined as the dose level at which at least one-third of patients experience a DLT during their first treatment course. The recommended dose level for the subsequent phase II study is defined as the preceding dose level before the MTD is attained.~If MTD is not reached, the recommended initial dose of the phase II part will be at the dose of paclitaxel 80 mg/m2 and gemcitabine 1200 mg/m2 (days 1, 8) with sunitinib 37.5 mg qd D2-D15.
Study: NCT02738346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Intravenous administration of Carboplatin AUC 5 at Day 1, Every 3 weeks, maximum 6 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Intravenous administration of 100mg/m²/day of Etoposide, Day 1 to Day 3 Every 3 weeks, maximum 6 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: Per os administration of 2.3 mg / m2 of Topotecan, Day 1 to Day 5 Every 3 weeks, maximum 6 cycles

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CT scans
Description: The CT scan evaluations will be conducted during chemotherapy every 6 weeks

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CT scans
Description: The CT scan evaluations will be conducted during chemotherapy every 6 weeks
Study: NCT04510155

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Overnight fasting duration
Description: Subjects will adhere to overnight fasting protocol for 1 day

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Overnight fasting duration
Description: Subjects will adhere to overnight fasting protocol for 1 day
Study: NCT04487418

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electro cautery surgery
Description: Pre-anesthetics with therapeutic topic (benzocaine) will be administered and, as an anesthetic, or use of anesthetic drops (benzocaine or tetracaine) or local infiltrative anesthesia (2% lidocaine 1: 100,000 with adrenaline).~The surgery will be carried out with cauterization for incision of the lingual brake, division of the brake fibers and release, removing the brake fibers that are stored in the anterior ventral free parts of the tongue until reaching the base of the tongue, which are removed or cleaned, lingual movement, and the anterior axis of the tongue is repositioned or lingual brake in that region. No sutures will be performed and should be oriented on the formation of a pseudo-membranous repair plate in the second intention that will be formed between the first and the third day after surgery.~Postoperative care:~Guidance will be given to the person responsible for not bringing objects to the mouth that may hurt.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: High power diode laser surgery
Description: Pre-anesthetics with therapeutic topic (benzocaine) and as anesthetic or use of anesthetic eye drops (benzocaine or tetracaine) or local infiltrative anesthesia (2% lidocaine 1: 100,000 with adrenaline) will be administered. The surgery will be performed with a high power diode laser (TW Surgical, MMOptics - São Carlos - Brazil). 808 nm wavelength, which can be operated in continuous or interrupted mode. Wattages from 1 to 1.5 W, up to a maximum of 2 W, can be used and must carefully respect the histological characteristics of the target tissue and the signs of overheating and carbonization, so that the choice of parameters is dynamic and very dependent on experience, mastery and care for the operator.~Preoperative care: Guidance will be given to the person responsible for not bringing objects to the mouth that may hurt.
Study: NCT01748006

Intervention type: OTHER
Intervention: Standard of care therapy for severe decompensated heart failure
Study: NCT01366534

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Crucell's replication deficient adenovirus type 35 circumsporozoite malaria vaccine (Ad35.CS.01)
Description: One dose will be administered intramuscularly at Study Day 0.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' malaria vaccine 257049 (2 doses)
Description: Two doses will be administered intramuscularly at monthly intervals

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK Biologicals' malaria vaccine 257049 (3 doses)
Description: Three doses will be administered intramuscularly at monthly intervals

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sporozoite challenge
Description: Subjects were challenged with sporozoite-infected mosquitoes to determine whether immune protective response had been induced by vaccination.
Study: NCT03959345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination therapy group
Description: Adult patients with MSSA bacteraemia will be randomized to Combination therapy group: patients will receive intravenous cloxacillin 2g/4h and fosfomycin 3 g/6h for the duration of 7 days treatment. After the first week, antibiotic treatment and duration will be decided by responsible clinician following clinical practice.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard therapy group
Description: Adult patients with MSSA bacteraemia will be randomized to Standard therapy group: patients will receive intravenous cloxacillin 2g/4h for the duration of 7 days IV treatment. After the first week, antibiotic treatment and duration will be decided by responsible clinician following clinical practice.
Study: NCT01695460

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: D3 Vitamin ®
Description: Vitamin D and placebo supplied as tablets in containers of 124. The containers must be kept in dry and not too hot environment.~All subjects randomized to vitamin D, will receive 100 micrograms of vitamin D3/day, equivalent to 4000 IU. Vitamin D is administered orally 1 time a day with breakfast.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02564068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: To test that intranasal oxytocin administration blunts the deleterious hypoxia/hypercapnia induced changes in heart rate that occur during nocturnal apnea in patients with OSA, we will examine the changes in heart rate in a group of patients that have recently been diagnosed with OSA. 8 subjects that have recently undergone a standard in the sleep-lab diagnostic polysomnography (per standard of care medical guidelines, and not for research purposes) and have been diagnosed with OSA will be recruited into a study to assess the beneficial effects of oxytocin treatment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: To test that intranasal oxytocin administration blunts the deleterious hypoxia/hypercapnia induced changes in heart rate that occur during nocturnal apnea in patients with OSA, we will examine the changes in heart rate in a group of patients that have recently been diagnosed with OSA. 8 subjects that have recently undergone a standard in the sleep-lab diagnostic polysomnography (per standard of care medical guidelines, and not for research purposes) and have been diagnosed with OSA will be recruited into a study to assess the beneficial effects of oxytocin treatment.
Study: NCT02027272

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Intravenous Dexamethasone 12 mg, 2 doses, 12 hours apart

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: Intravenous Dexamethasone 12 mg, 2 doses, 12 hours apart
Study: NCT04572685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate
Description: A long acting extended release injectable suspension intended for monthly intramuscular administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate
Description: A long acting extended release injectable suspension intended for monthly intramuscular administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone Palmitate
Description: A long acting extended release injectable suspension intended for monthly intramuscular administration
Study: NCT00186849

Intervention type: DRUG
Group type: OTHER
Intervention: Topotecan, Cyclophosphamide, Cisplatin, Doxorubicin, Etoposide, Ifosfamide, Carboplatin
Description: See Detailed Description section for details of treatment interventions.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Peripheral Blood Stem Cell Transplant
Description: See Detailed Description section for details of treatment interventions.
Study: NCT03664011

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 730357 mixed with [C-14]BI 730357 BS
Description: Oral Solution
Study: NCT03534713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: carboplatin aera Under curve 5 on day 1, every 21 days during 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: paclitaxel 175 mg/m² on day 1, every 21 days during 3 cycles
Study: NCT02746549

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: renal perfusion
Description: measurement of renal perfusion with MRI arterial spin labelling technique

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: renal perfusion
Description: measurement of renal perfusion with MRI arterial spin labelling technique
Study: NCT01086813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3043
Description: single dose/IV, bolus over 60secs - infusion over 30 mins
Study: NCT04051008

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Default - use of online grocery shopping platform with default shopping carts
Description: The Defaults intervention, will augment the Online intervention, showing participants a default cart when they log into their online grocery shopping accounts. They will be told that their cart has been filled with items that conform to a diabetic diet and can be used to make the recipes from provided recipe cards, and that they may modify their cart as they like.
Study: NCT04653961

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DreaMed Advisor Pro DSS-MDI algorithm
Description: The DreaMed Advisor Pro software is a proprietary algorithm, designed to provide a comprehensive analysis of individual diabetes data which consists of glucose levels and insulin delivery history. the Advisor Pro algorithm identifies glucose patterns and their possible causes, which may hamper the patient's glucose control, and recommend on adjustment to the patient-specific insulin treatment profiles as well as suggestions for personalized diabetes management tips (such as timing of meal boluses, bolus delivery compliance and personalized glucose targets).
Study: NCT03378232

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Olive Oil
Description: Each participant was instructed to consume the dietary supplement on a daily basis for 12 weeks.
Study: NCT04111471

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotics
Description: Enrolled patients will receive 10 grams of inulin daily for 21 days

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Enrolled patients will receive 5.6 grams of placebo powder daily for 21 days
Study: NCT02317783

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]Flutemetamol
Description: Brain scan with imaging tracer that binds to amyloid plaques

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F]fluoro-2-deoxy-D-glucose (FDG)
Description: Brain scan with imaging tracer used for measuring glucose metabolism in the assessment, diagnosis, and staging of patients with cancer

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Functional Magnetic Resonance Imaging (fMRI)
Description: Brain scan to assess regions of abnormal volume and density
Study: NCT03534713

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin 40mg/m² given once a week during 5 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: Cisplatin 40mg/m² given once a week during 5 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 45 gray to the pelvis and para aortic area over 5 weeks + intracavitary brachytherapy alone or prior to surgery, depending on response to treatment according to the current guidelines

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: 45 gray to the pelvis and para aortic area over 5 weeks + intracavitary brachytherapy alone or prior to surgery, depending on response to treatment according to the current guidelines